HMG CoA reductase inhibitors (statins) for kidney transplant recipients (Q24200984)

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Inflammation in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Pravastatin improves low-density lipoprotein oxidation in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

The effects of lipid-lowering agents on acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Simvastatin effect on NK cells activity in vivo: a double-blind randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effect of alternate-day prednisone on plasma lipids in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effects of pravastatin treatment on blood pressure regulation after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

A prudent algorithm for hyperlipoproteinemia in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Cardiovascular risk factors and diseases after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Patient survival after renal transplantation III: the effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Prevention of cardiovascular disease in adult recipients of kidney transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

KDIGO clinical practice guideline for the care of kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Statin use after renal transplantation: a systematic quality review of trial-based evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Hyperlipidemia and cardiovascular disease after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Metaanalysis of statins and survival in de novo cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

HMG CoA reductase inhibitors (statins) for dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Cyclosporin and serum lipids in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Effect of statin treatment on oxidative stress and renal function in renal transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Cholesterol reduction in cyclosporine-treated renal transplant patients: effect on platelet-derived growth factor levels and platelet activation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Cardiovascular morbidity and risk factors in renal transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Lovastatin treatment of hypercholesterolemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Risk factors predicting chronic rejection of renal allografts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Which dosage of simvastatin in renal transplant patients?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021

Incidence and predictors of myocardial infarction after kidney transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005019.PUB4

7 January 2021